Article info
PDFPostScript
Letter
Antiganglioside antibodies in Guillain-Barré syndrome associated with SARS-CoV-2 infection
- Correspondence to Dr Carlo Civardi, Department of Neurology, ASL To4, Ivrea, Piedmont, Italy; c_civardi{at}yahoo.com
Citation
Antiganglioside antibodies in Guillain-Barré syndrome associated with SARS-CoV-2 infection
Publication history
- Received June 17, 2020
- Revised July 30, 2020
- Accepted August 6, 2020
- First published August 28, 2020.
Online issue publication
December 11, 2020
Article Versions
- Previous version (16 November 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage